×

Business / Stock Market

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S

Published Apr 06 2021 at 10:00 PM GMT

Benzinga @benzinga.com

Add to Collections
Report Post

Continue reading at benzinga.com

Key
Points

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S.

Credit

Tags

Continue reading at benzinga.com

Posted in Business, Stock Market

Stats

Published Apr 6, 2021 10:00 PM GMT